Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1

Status

Completed 5Not yet recruiting 3Recruiting 2Enrolling by invitation 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Myasthenia Gravis 2

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × rozanolixizumab × Clear all
NCT07246564 2026-05-22

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 4 Recruiting
40 enrolled

Myasthenia Gravis

NCT06149559 2026-05-08

roMyG

UCB Pharma

Phase 2/3 Recruiting
12 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡